Koper, Marta J.
Van Schoor, Evelien
Ospitalieri, Simona
Vandenberghe, Rik
Vandenbulcke, Mathieu
von Arnim, Christine A. F.
Tousseyn, Thomas
Balusu, Sriram
De Strooper, Bart http://orcid.org/0000-0001-5455-5819
Thal, Dietmar Rudolf http://orcid.org/0000-0002-1036-1075
Funding for this research was provided by:
FWO (G0F8516N, 1S46219N)
IWT (135043)
Methusalem
KU Leuven (C14-17-107)
Article History
Received: 22 August 2019
Revised: 5 November 2019
Accepted: 21 November 2019
First Online: 4 December 2019
Compliance with ethical standards
:
: DRT received consultant honorary from GE Healthcare (UK) and Covance Laboratories (UK), speaker honorary from Novartis Pharma AG (Switzerland), travel reimbursement from GE Healthcare (UK) and UCB (Belgium) and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium). BDS collaborated with Janssen Pharmaceutical companies (Belgium), Abbvie (USA) and received consulting fees from Eisai (Japan). None related to the work in this paper. RV’s institution has clinical trial agreements (RV as PI) with AbbVie, Genentech, Novartis, and Roche, material transfer agreements (RV as PI) with Avid a subsidiary of EliLilly, and consultancy agreements (RV as PI) with Prevail Therapeutics and Rodin Therapeutics. CAFvA received honoraria from serving on the scientific advisory board of Nutricia GmbH, Roche, Dr. Willmar Schwabe GmbH and Honkong University Research council and has received funding for travel and speaker honoraria from Nutricia GmbH, Lilly Deutschland GmbH, Desitin Arzneimittel GmbH, Biogen, Roche and Dr. Willmar Schwabe GmbH &Co. KG.